other material
confidence high
sentiment neutral
materiality 0.70
Atara Biotherapeutics establishes $100M ATM equity facility with TD Cowen
Atara Biotherapeutics, Inc.
- Entered into an at-the-market (ATM) sales agreement with TD Cowen for up to $100M in common stock.
- Commission of up to 3.0% on gross proceeds; company controls timing and size of sales.
- Replaces existing 2021 ATM facility once new shelf registration statement becomes effective.
- No sales permitted until the registration statement is declared effective by the SEC.